Matt Kong

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Cooley advised Etsy, a two-sided online marketplace that connect millions of passionate and creative buyers and sellers around the world, on its offering of $1 billion aggregate principal amount of 0.25% convertible senior notes due 2028. Partners Yvan-Claude Pierre, Nicole Brookshire and Rupa Briggs led the Cooley team advising Etsy.

Cooley advised Dynavax Technologies on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. Dynavax Technologies, whose securities trade on the Nasdaq Capital Market under the symbol DVAX, is a biopharmaceutical company focused on developing and commercializing novel vaccines. Partners Steve Przesmicki, Mischi a Marca and Jason Savich le the Cooley team.